Yingcai Feng
BeiGene (China)(CN)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Melanoma and MAPK Pathways
Most-Cited Works
- → Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development(2020)72 cited
- → Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage(2021)71 cited
- → BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF -Mutated Colorectal Cancers(2015)71 cited
- → Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy(2024)65 cited
- → Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab(2019)16 cited
- → BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models(2023)7 cited
- → 699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models(2020)5 cited
- → Abstract 4692: BGB-283, a novel RAF kinase and EGFR dual inhibitor, displays potent antitumor activity in B-RAF mutated colorectal cancers(2015)1 cited